The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on interventions for the monitoring and treatment of congestive heart failure (CHF). The report will serve as the basis for the October 29, 2015 public meeting of the California Technology Assessment Forum (CTAF), a core program of ICER. ICER’s report for CTAF will evaluate the health and economic outcomes of two interventions: the CardioMEMS™ HF system (St. Jude Medical) to monitor patients with CHF, and the drug Entresto™ (Novartis AG) for the treatment of CHF. The scoping document will be open to public comment for a period of one week.
Members of the public are encouraged to submit suggested refinements or additions to the scoping document via email to firstname.lastname@example.org. Comments must be received by 5:00 PM PT on Thursday, July 16 and must adhere to guidelines described in the CTAF public comment guide.
The report will form the basis of the October 29 CTAF public meeting, at which an independent Panel will vote on key questions raised in the report, and a policy roundtable will discuss recommendations to apply the evidence to policy and practice.
Additional key dates for the draft report, as well as further information about the October meeting, are included below:
Report Timeline and Public Comment Process
An outline of the key dates for the public comment process are outlined below. More information on ICER’s stakeholder engagement policy is available on the CTAF website.
July 9: Scoping Document Posted
July 9 – 16: Public comment period for scoping document
Sept. 10: Draft report and voting questions posted
Sept. 10 – 24: Public comment period for draft report and voting questions
Oct. 8: Revised draft report posted
Oct. 8 – 28: CTAF Panel reviews revised draft report
Oct. 29: Public meeting
CTAF Meeting Details
Date: October 29, 2015
Location: 1111 Broadway, 7th Floor
Oakland, CA 94607
Meeting details and registration information will be posted to the CTAF website as they become available.